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INTRODUCTION
NHL accounts for approximately 7% of cancers in patients
under 20 years, or approximately 800 cases annually amongst
COG institutions. With current therapies based on histology,
cure rates range from 70% to over 90%, even for disseminated
disease. However, two major challenges remain and need to be
overcome: (i) to optimize upfront treatment to prevent relapse
since prognosis for patients with refractory of relapsed disease
remains very poor and (ii) minimize long term side effects sur-
vivors. Therefore, a major objective for the pediatric NHL ﬁeld is
to utilize novel targeted therapies to not only improve outcomes
for patients but also to decrease bystander organ toxicities and
late effects.
STATE OF THE DISEASE—CLINICAL
Overview
Malignant lymphomas (Hodgkin and non-Hodgkin) are the
third most common malignancy among children and adolescents.
For pediatric NHL in the US, the estimated 5-year survival rates
range from approximately 70% to >95%, depending on stage and
histology. Unlike adult lymphomas, pediatric NHL more often
presents as high-grade tumors with disseminated disease with
extranodal involvement, requiring distinct treatment approaches.
In children the median age at presentation is 10 years, while
presentation below 3 years of age is infrequent. NHL has a
male predominance and is almost twice as common in whites
compared to African Americans. Speciﬁc populations at risk for
NHL include those with congenital or acquired immunodeﬁcien-
cies, including patients on immune suppression after transplant
and HIV infection [2].
Current Outcomes
Lymphoblastic lymphoma (LBL). LBL therapy is based on
ALL protocols that achieve survival rates of >90% for low-stage
disease and >80% for advanced-stage disease [3]. CNS disease
portends worse prognosis, but is less common in T-LBL than in T-
ALL. COG demonstrated that minimal disseminated disease at
diagnosis has prognostic value, as indicated by ﬂow cytometric
evidence of tumor cells in bone marrow [4]. Consequently, the
COG now risk-stratiﬁes patients with T-LBL based on the pres-
ence of minimal disease in the bone marrow at presentation. CNS
prophylaxis is needed for LBL; however, chemotherapy is as
effective as prophylactic cranial irradiation in CNS-negative
patients, even with advanced-stage disease [5–8].
Burkitt lymphoma (BL). The overall survival for BL exceeds
85% irrespective of stage, except for patients with CNS involve-
ment where event free survival is approximately 80% [9]. Poor
prognostic features are high LDH at presentation, cytogenetic
abnormalities such as 7q, 13q-, and partial duplication of 1q,
and a suboptimal response to initial cytoreduction therapy.
Completely resected, localized BL is curable with minimal thera-
py consisting of two courses of COPAD (cyclophosphamide,
vincristine, prednisolone, and doxorubicin) without intrathecal
chemotherapy with a 4 year OS of 99.2% [10]. Advanced stage
BL, however, requires aggressive combination chemotherapy with
CNS prophylaxis. High dose cyclophosphamide, methotrexate,
cytarabine, and low-doses of anthracyclines are currently used,
with or without epipodophyllotoxins. For intermediate-risk
patients (group B) The French–American–British (FAB-96;
CCG5961) study successfully reduced the cumulative dose of
cyclophosphamide and omitted multi-agent maintenance cycle
without compromising an EFS of 90% [11]. For high-risk (group
C) patients EFS is 79–84%; however, a reduction in intensity and
duration of therapy resulted in inferior outcome. This study con-
ﬁrmed that CNS radiation can be omitted for patients with CNS
involvement at diagnosis without impacting the outcome.
Diffuse large B cell lymphoma (DLBCL). With current treat-
ment children and young adults with Diffuse large B cell
Non-Hodgkin lymphomas account for approximately 7% of
cancers diagnosed in patients less than 20 years of age, with ap-
proximately 800 cases diagnosed annually at COG institutions.
With current therapies, cure rates range from 70% to over 90%,
even for children with disseminated disease. However, two major
challenges need to be overcome: (i) to optimize upfront treatment to
prevent relapse since prognosis for patients with relapsed disease
remains poor and (ii) minimize long-term side effects in survivors.
Hence, the future initiatives for the treatment of pediatric NHL are
to utilize novel targeted therapies to not only improve outcomes
but to decrease bystander organ toxicities and late effects. Pediatr
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lymphoma (DLBCL) have a 5-year OS of 90%. In DLBCL,
females, c-myc rearrangements, primary mediastinal B cell
lymphoma (PMBL), and LDH of >500 U/L confers the poorer
prognosis [12]. As opposed to adults with DLBCL, best results
in pediatric DLBCL have been achieved using BL regimens
[13]. Therefore, in pediatric DLBCL, treatment traditionally
includes intrathecal chemotherapy for CNS prophylaxis.
However, since CNS involvement is infrequent in DLBCL,
it is unclear if intensive CNS-directed therapy is necessary
[13,14].
Anaplastic large cell lymphoma. ALCL was ﬁrst described in
1985 as a clinicopathologic variant of LCL [15]. ALCL are typi-
cally CD30þ and associated with chromosomal rearrangements
involving a translocation which fuses the NPM, nucleolar phos-
phoprotein gene, on chromosome 5q35 with anaplastic lymphoma
kinase (ALK), on chromosome 2p23. ALCL accounts for 8–13%
of childhood NHL and 30–40% of pediatric LCL. Although bone
marrow and central nervous system involvement is uncommon
most have advanced disease at presentation. One-third present
with localized disease [16]. The optimal treatment strategy
remains to be deﬁned, with survival ranges from 70% to 85%,
regardless of treatment [17–19]. Vinblastine has been demonstrat-
ed to have signiﬁcant activity in relapsed ALCL [1] and has been
incorporated as front-line treatment into two randomized trials—a
multi-national European trial (ALCL99) and in the APO (COG
trial in the United States). The COG study ANHL0131 demon-
strated no beneﬁt of the addition of vinblastine [20]. In ALCL99,
patients receiving vinblastine maintenance for 1 year had a better
1 year EFS (91%) than those without vinblastine (74%); however,
the 2-year EFS fell to 73% for both groups [21]. Additionally,
ALCL99 demonstrated, methotrexate given as 1 g/m2 over
24 hours was comparable to 3 g/m2 over 3 hour infusions without
intrathecal chemotherapy, but the latter had less acute toxicity
[22]. The remarkable activity and relatively little toxicity of bren-
tuximab vedotin (tubulin-inhibitor conjugated monoclonal anti-
CD30) and crizotinib (oral ALK inhibitor) in relapsed ALCL
patients [23,24], has lead cooperative groups to pursue testing
the efﬁcacy and toxicity of adding these two biologic targeted
agents with standard chemotherapy in newly diagnosed pediatric
ALCL patients.
Post-transplant lymphoproliferative diseases (PTLD). PTLD
are typically associated with Epstein–Barr virus (EBV) reactiva-
tion in organ or stem cell transplantation. Solid organ transplant
(SOT) related PTLD is more common in children than in adults.
In children, PTLD is typically of B-cell origin. In the USA,
approximately 150 new cases of PTLD are diagnosed in children
each year. These highly immunogenic tumors, amenable to im-
mune based therapies, have Type III latency, where all latent EBV
proteins are expressed. Many treatments for childhood PTLD
have been explored but few multicenter collaborative studies are
reported. Withdrawal or reduction of immunosuppression is a
standard ﬁrst approach for PTLD but success depends on whether
the immune function recovers promptly enough to eradicate EBV-
infected B cells. After SOT, radiotherapy or surgical resection for
localized disease can achieve complete remissions [25]. In a study
of children with PTLD that was refractory to reduction of immune
suppression, six cycles of low dose cyclophosphamide and pred-
nisone and six doses of rituximab (monoclonal anti-CD20 anti-
body) were given. The 2-year EFS and OS was 71% and 83%,
respectively [25].
STATE OF THE DISEASE—BIOLOGICAL
Molecular Targeting of NHL Cells Using antibodies
Among the more studied antibody targets for NHL include the
overexpression of CD20 or CD30.
CD20. Rituximab is a mouse/human chimeric monoclonal an-
tibody targeting CD20 which is highly expressed in BL and
DLBCL. In adults, the addition of rituximab to CHOP chemother-
apy is beneﬁcial for DLBCL [26,27] and can be given safely in
combination with intensive BL therapy [28]. In children, single-
agent rituximab showed activity for BL in a phase II window
study for newly diagnosed patients [29]. Adult data suggest that
rituximab may allow diminished use of agents with serious acute
or late toxicities, warranting further study [27]. COG ANHL01P1
demonstrated the safety of adding rituximab to the FAB96 (CCG
5961) backbone [30]. Based on these results, the recently opened
international collaborative study INT-B-NHL ritux 2010 (COG
ANHL1131) will test the beneﬁt of adding rituximab to the
FAB96 backbone in high-risk pediatric BL and DLBCL in a
randomized phase III study. Additionally, this study will test
safety and efﬁcacy of the DA-EPOCH-rituximab regimen [31]
in pediatric PMBL in a phase II study.
CD30. Current studies in adults with ALCL suggest that CD30
can be targeted with the tubulin inhibitor conjugate anti-CD30
monoclonal antibody, brentuximab vedotin. The data in adults
with relapsed ALCL demonstrate signiﬁcant activity with relative-
ly little toxicity [32]. Experience in combining brentuximab vedo-
tin with chemotherapy is emerging and pediatric experience is
limited. COG is pursuing studies to test safety and efﬁcacy
in combination with chemotherapy of brentuximab vedotin in
CD30(þ) lymphoma.
Targeting the ALK Pathway
In ALCL, the chromosome 5q35;2p23 translocation links the
amino terminus of nucleophosmin (NPM) with the catalytic
domain of ALK [33]. This oncogenic chimeric NPM-ALK protein
is thought to trigger antiapoptotic signals via phosphatidylinositol
3-kinase/AKT and in conjunction with secondary molecular
events leads to lymphoma. The remarkable activity and relatively
little toxicity of brentuximab vedotin (tubulin-inhibitor conjugat-
ed monoclonal anti-CD30) and crizotinib (oral ALK inhibitor)
[34] in relapsed ALCL patients [23,24], will lead COG to pursue
testing the efﬁcacy and toxicity of adding this two biologic tar-
geted agents with standard chemotherapy in newly diagnosed
pediatric ALCL patients.
EBV
In vitro EBV infected B lymphocytes transform into long-lived
B lymphoblastoid cell lines (LCLs) expressing all nine latency-
associated proteins. These type 3 latency cells are highly immu-
nogenic, and are observed in EBV-associated lymphomas in
individuals who are severely immunocompromised by organ
transplantation (PTLD), HIV infection or immunodeﬁciency syn-
dromes. Such tumors are usually well controlled by the adoptive
transfer of EBV-speciﬁc cytotoxic T lymphocytes (EBV-CTL).
EBV-CTL have been shown to be highly effective in EBV-
associated lymphomas [35], but due to regulatory restrictions
been limited to only a few centers. Nevertheless, several groups
980 Bollard et al.
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both in Europe and the USA are now pursuing multicenter studies
using adoptive EBV-CTL therapy in the treatment of EBV-asso-
ciated PTLD in pediatrics.
CONCLUSIONS FROM RECENT STUDIES
CONDUCTED BY COG FOR NHL
As discussed above, numerous advances have been made in
the treatment of pediatric NHL both in Europe and in the USA
over the past decade. Seven major studies have recently been
completed by the children’s oncology group and are highlighted
as follows:
Pilot Study to evaluate the feasibility of adding rituximab
to standard therapy for stage III/IV mature B-cell NHL.
ANHL01P1 found no serious toxicities associated with rituximab
infusion along with no unexpected increase in toxicity compared
to chemotherapy alone. Rituximab pharmacokinetics found simi-
lar drug exposures to what has been observed in adult studies,
with rituximab remaining detected in serum up to 6 months after
last dose. The 3-year EFS rate was 93% (95% CI: 78–98%) for
group B and 86% (95% CI: 70–94%) [30] for group C patients
[36]. the study provided the key feasibility data for the current
international intergroup study, INT-B-NHL ritux 2010 (COG
ANHL1131).
Collaboration with the NCI Lymphoma SPECS project, to
compare adult BL and DLBCL with pediatric BL/DLBCL.
This study, found that compared with adult BL and DLBCL,
the histologic diagnosis of pediatric DLBCL and BL is more
likely (approximately 20–30% of cases) to be re-classiﬁed by
molecular gene expression proﬁle. Another ﬁnding was that in
pediatric molecular DLBCL up to 75% of cases have over-expres-
sion of c-MYC by either translocation or gene gains or ampliﬁca-
tions [37]. these data suggest that pediatric DLBCL usually has a
more aggressive biology and provides justiﬁcation for the use of
BL regimens.
Phase II study adding rituximab to ifosfamide, carbo-
platin, etoposide or relapsed CD20þ pediatric lymphoma
(ANHL0121). No signiﬁcant toxicity was observed by adding
rituximab to chemotherapy. CRs were observed in 3/6 patients
with DLBCL and 4/14 patients with BL, with additional 5/14 PRs
in BL patients. This regimen is now considered a standard of care
for pediatric relapsed CD20þ lymphoma internationally [38].
Cooperative group trial for post-transplant lymphoproli-
ferative disease. ANHL 0221 was a phase II study of a low-dose
chemotherapy backbone (cyclophosphamide and prednisone) for
six cycles plus weekly rituximab through ﬁrst two cycles for
progressive PTLD after solid organ transplantation. there was
no increase in grade iii/iv toxicity observed for cycles with ritux-
imab. The 2-year event-free survival (EFS) rate was 71% (95%
CI: 57–82%) and 2-year overall survival (OS) rate for PTLD was
83% (95% CI: 69–91%). interestingly, neither histology, clonality,
stage, early response nor response at end of therapy predicted
outcome [25].
Using minimal marrow disease at diagnosis (MMD) to
identify good-risk patients in T-cell lymphoblastic lymphoma.
In 99 children with T-LBL treated on the COG a5971 study,
2-year EFS was 68  11% for patients with >1% T-LBL cells
in bone marrow by ﬂow cytometry methods, as compared to
91  4% for patients with <1% marrow involvement [4]. the
open AALL0434 study is for T-cell LBL patients with
disseminated disease and patients are risk stratiﬁed based on
MDD at diagnosis.
Phase III study (ANHL0131) for advanced stage anaplastic
large cell lymphoma comparing the efﬁcacy of vinblastine
versus vinblastine in maintenance. As discussed earlier, no
difference was observed between the two arms and the study
was closed early due to futility [20].
Randomized 2 T 2 factorial design study for patients with
lymphoblastic lymphoma. The COG A5971 study was designed
to determine: (a) the affect of induction intensiﬁcation and (b) the
best method for CNS prophylaxis (high-dose methotrexate in
consolidation versus intrathecal methotrexate in maintenance).
We found no beneﬁt in outcome but increase toxicity with induc-
tion intensiﬁcation and no difference in method of CNS prophy-
laxis [39]. This study also produced the largest series of pediatric
patients with localized LBL and demonstrated excellent outcome
with reduction of intrathecal treatments [40].
STRATEGIC APPROACH: TARGETED THERAPIES
Evaluating the Efficacy of Anti-CD20 Therapy for
Pediatric Patients With Burkitt Lymphoma and Diffuse
Large Cell Lymphoma
Rituximab in association with chemotherapy has become the
standard treatment for DLBCL in adults. However, there are limit-
ed data for the use of rituximab in childhood B-cell lymphomas.
Results from adult B-cell lymphoma cannot be assumed to apply
to children because of differences in the biology of childhood
DLBCL [37] and because >75% of childhood B-cell lymphoma
are Burkitt lymphoma/leukemia, where efﬁcacy of rituximab has
never undergone evaluation in a prospective randomized trial (ei-
ther in adults or children). Because EFS is already high in children
with the current intensive chemotherapy regimen, and because
rituximab is an expensive medication, which could produce poten-
tial severe side effects (e.g., prolonged lymphoid B cell depletion
and infections), a large randomized trial is necessary to evaluate
whether rituximab can add beneﬁt to the current chemotherapy
regimen. International collaboration is required to accrue sufﬁcient
number of patients in this population.
Exploring a New Therapeutic Approach for PMBL
Two pilot studies completed in children provide the prelimi-
nary evidence regarding the safety and activity of rituximab in
B-cell malignancies. In FAB96 (CCG 5961) EFS for PBML was
70% and in the COG ANHL01P1, of the four patients with
PMBL, two had recurrent disease, accounting for two of the three
recurrences observed in the 45 group B patients. These results
therefore suggested that the FAB96 backbone, even with addition
of rituximab may not be optimal for this patient population. In
an effort to maximize cure rates of B-cell malignancies, investi-
gators have attempted to improve the therapeutic index of che-
motherapy by taking advantage of increased sensitivity of highly
proliferative tumors to prolonged exposure to low concentrations
of chemotherapy. Based on data demonstrating decreased chemo-
resistance in vitro with low-dose, continuous administration
of vincristine and doxorubicin, as well as synergistic effect of
etoposide with CHOP, researchers at the National Cancer Institute
initiated the dose-adjusted etoposide, prednisone, vincristine,
COG Studies for NHL 981
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cyclophosphamide, doxorubicin (DA-EPOCH-R) regimen for
adults with PMBL [41]. In this regimen, rituximab is given along
with vincristine, doxorubicin, and etoposide which are adminis-
tered as a continuous infusion over 4 days. Doses of doxorubicin,
cyclophosphamide, and etoposide were increased by 20% per
cycle until the patients experienced prolonged (>1 week) neutro-
penia or platelet count less than 25  10E9/L. This regimen
showed a 100% OS and a PFS of >95% for adult patients with
PMBL [41]. Based on these studies, the efﬁcacy and tolerability
of the DA-EPOCH-R regimen in children is currently being in-
vestigated in an international/intergroup trial (ANHL1131) as a
separate arm for pediatric patients with PMBL.
Evaluating Targeted Therapies Using Small Molecules
and Antibodies for the Treatment of ALCL
Despite numerous treatment strategies over the last 20 years
for pediatric ALCL, relapse rates remain 25–30%. Hence the
COG will explore two novel targeted therapies for the treatment
of this disease. The hypotheses to be tested are: (i) that the novel
antibody-drug conjugate brentuximab vedotin a tubulin inhibitor
auristatin conjugated into a humanized monoclonal anti-CD30
antibody, given in combination with standard chemotherapy will
be tolerable in pediatric ALCL and (ii) that the novel agent
crizotinib, an oral small molecule inhibitor of the NPM-ALK
fusion protein, given in combination with standard chemotherapy
will be tolerable in pediatric ALCL. The results of this pilot study
should allow the development of a follow-up trial which will test
whether these agents can improve survival in pediatric ALCL.
Moreover, the study aims to determine the prognostic signiﬁcance
of minimal disease at diagnosis and minimal residual disease as
measured by RT-PCR in peripheral blood.
NHL Biology and Therapeutic Target Identification
Aggressive B-cell lymphomas. From the Phase 3 International
Trial-ANHL1131 which will evaluate the potential prognostic val-
ue of minimal disseminated disease (MDD) and minimal residual
disease (MRD) at time points during therapy to correlate with
outcome, the MDD/MRD assay will be used as an assessment
tool to identify response and efﬁcacy of future targeted therapeutic
agents. Additionally, as part of this international effort, groups in
both Europe and the USA will also determine the molecular basis
of pediatric Burkitt lymphoma, primary mediastinal B-cell lym-
phoma, and diffuse large B-cell lymphoma using high density SNP
arrays on formalin ﬁxed tissues and next generation sequencing
technologies on available frozen tissues.
Anaplastic large cell lymphoma. Phosphoproteomic studies
are aimed at identifying novel therapeutic targets in ALK positive
ALCL. These studies have the potential to discover mechanisms
of resistance to small molecular inhibitors of ALK or anti-CD30
(SGN-35) therapy. In the upcoming ALCL study, correlative bi-
ology studies will be performed to monitor NPM-ALK transcript
levels in patients treated with crizotinib and SGN-35 as have been
performed previously on other COG studies (e.g., ADVL0912).
PET and Minimal Residual Disease (MRD) as
Prognostic Factors
In the ANHL1131 international trial, minimal residual disease
will be measured after COPADM1 (only for B-AL patients and
the same day as the PET(-CT) scan is performed) and at remission
assessment time (post the ﬁrst consolidation cycle). This will be
performed using a highly sensitive PCR assays. The prognostic
value of MRD in BM and PB before the second course will be
evaluated in B-AL patients and the prognostic value of MRD in
BM and PB at the remission assessment time will be evaluated in
patients in clinically complete remission at that time.
T-Cell Immunotherapeutic Approaches for NHL
Adoptive immunotherapy has an established place in the treat-
ment of viral infection and relapse after allogeneic hematopoietic
stem cell (HSC) transplantation [42–46]. Ongoing studies are now
exploring adoptive immunotherapy in relapsed low grade lympho-
ma after transplantation and EBV-associated malignancy [35,47].
In a three institution study of 114 patients, EBV-speciﬁc CTLs
were infused to prevent or treat PTLD with minimal toxicity. Of
101 receiving CTL infusions as prophylaxis none developed
PTLD. Of 13 patients treated for active disease, 11 achieved
durable complete remissions, and no relapse. In solid organ trans-
plant, in contrast to HSCT, PTLD usually arises in recipient
B-cells and no HLA matched donor is usually accessible. In the
absence of full matching between donor and recipient a partially
matched donor T cells would need to be effective through a
limited number of shared antigens. Alternatively, autologous T
cells can be used and in vivo functionally active CTL have been
successfully generated from patients on prolonged immunosup-
pression [48–51]. When autologous CTL were used pre-emp-
tively, no patient developed PTLD. These studies allayed
concerns that autologous EBV-speciﬁc CTL might induce rejec-
tion of the transplanted solid organ [48,49]. While EBV-speciﬁc T
cell therapy is effective the approach is restricted by their patient-
speciﬁc nature and limited availability. These constraints can be
overcome by creation of a bank of HLA-typed EBV-speciﬁc
T-cell lines. This third-party approach was tested by Haque
et al. [52], who manufactured a bank of polyclonal EBV CTL
lines to treat EBV-associated diseases in patients undergoing
HSCT or solid organ transplantation. The lines were generated
from blood donors and selection of the CTL were based primarily
on the best HLA match [53]. In a phase II multicenter trial
(19 transplant centers) for EBV positive PTLD not responding
to conventional therapy, 33 patients received the best-HLA-
matched ‘‘off-the-shelf’’ product [54]. Overall response rates
were 64% at 5 weeks, and 52% at 6 months. Similar results
have been reported from the UK and elsewhere in the USA
[55–59]. Hence, this approach shows promise, and warrants fur-
ther testing in deﬁnitive studies.
KEY CLINICAL TRIALS BEING PURSUED BY COG
FOR PEDIATRIC NHL
Pivotal Phase 3 International Trial—ANHL1131
This international intergroup study involving groups from
Europe, USA, Canada, and Australasia (AIEOP, BSPHO,
DCOG, HSPHO, PPLLSG, SEHOP, SFCE, UK NCRI CCL
CSG, and COG) is open to patients with advanced stage B-cell
NHL (patients with stage III disease and LDH greater than two
times normal and any patient with stage IV disease) or mature
B-cell leukemia (>25% blasts in marrow) EXCLUDING patients
with PMBL. The study aims to determine whether six infusions of
982 Bollard et al.
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rituximab added to a standard intensive chemotherapy regimen
(‘‘LMB’’ therapy) will improve the event free survival compared
with the chemotherapy regimen alone. Children and adolescents
with aggressive B-cell NHL currently have an event free survival
rate of less than 90% with current therapy. Six hundred patients
(40% from COG) from the nine international pediatric cancer
cooperative groups will be accrued over 5 years to determine if
rituximab reduces the risk of relapse by 50%. The secondary
objectives of this study are to: (i) determine the effect of the
intensive chemotherapy regimen with and without rituximab on
immunoglobulin levels (and need for immunoglobulin infusions),
B-cell counts, pre-existing vaccine titers and response to vaccina-
tion at 1 year post completion of therapy and (ii) evaluate the
potential prognostic value of MDD and MRD at two time points
during therapy in correlation with outcome and (iii) to evaluate
feasibility and prognostic value of PET scans in childhood pedi-
atric B-cell NHL.
Phase 2 Studies
ANHL12P1. For the treatment of pediatric patients with
ALCL, the COG plans to determine the tolerability of brentux-
imab vedotin given in combination with standard chemotherapy
(ALCL99) and to determine the tolerability of crizotinib given in
combination with standard chemotherapy (ALCL99). Patients will
be randomized to two arms: Arm A will add brentuximab vedotin
to standard chemotherapy per ALCL99 (3 g/m2 methotrexate and
no intrathecal chemotherapy) and Arm B will add crizotinib to
standard chemotherapy per ALCL99 (3 g/m2 methotrexate and no
intrathecal chemotherapy). This design will allow for the deter-
mination of toxicity and outcome of brentuximab vedotin and
crizotinib with chemotherapy.
Development of a new PTLD study to incorporate T-cell
therapies. To build on the success of the recently completed ﬁrst
cooperative group trial for post-transplant lymphoproliferative
disease (ANHL0221) the COG proposes to evaluate the use of
‘‘off the shelf’’ third party allogeneic EBV-CTLs in combination
with ANHL0221 chemotherapy. This would represent the ﬁrst
multicenter study of its kind combining low dose chemotherapy
and antibody therapy with ‘‘off the shelf’’ antigen-speciﬁc T cell
therapy for this disease.
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